Eli Lilly

The approval allows a simplified once-monthly 200 mg maintenance dose of Omvoh (mirikizumab-mrkz) for adults with moderately to…

Eli Lilly highlights findings from two late-stage trials demonstrating orforglipron’s effectiveness in improving blood sugar…

The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing healthcare…

Seven out of the top 20 companies registered over 10 per cent YoY revenue growth from 2023 to 2024

The Obesity Gurukul program will aim to offer a structured and immersive learning experience for over 20,000 healthcare…

Eli Lilly’s clinical data with orforglipron in patients with diabetes supports the drug’s potential as an obesity treatment, as…

Doctors have warned of the risk of overuse and misuse, cautioning that patients will see such medications as an easy, quick fix,…

ATMF report recommends practical solutions whereby companies can bring about the fundamental shift that is required to scale up…

US pharma manufacturing sees investment surge amid tariff shifts, while BRICS nations push regulatory reforms to expand biosimilar…

Growing patient awareness and emerging therapies drive obesity drug market expansion across the US, Europe, and Japan